CA19-9/Sialyl Lewis A Antibody (121SLE) - Azide and BSA Free, Novus Biologicals™

CA19-9/Sialyl Lewisa

Monoclonal

1 mg/mL

Flow Cytometry 0.5 - 1 ug/million cells, Immunocytochemistry/Immunofluorescence 0.5 - 1 ug/ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml

Mouse

400 kDa

200 μg

Primary

Human

Supernatant

Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin)

121SLE

Unconjugated

PBS with No Preservative

Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le).

Tissue culture supernatant

RUO

CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is excellent for staining of formalin-fixed, paraffin-embedded tissues.

Store at -20 to -80C. Avoid freeze-thaw cycles.

IgM κ